Stoke Therapeutics (NASDAQ: STOK) net income
Stoke Therapeutics reported a net loss of $6.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $89.0m. Earnings per share were −$0.12.
Fiscal 2025 is the highest of the 8 fiscal years on record for Stoke Therapeutics. It reported a loss in 8 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$6.9m | — | −3.7% | −$0.12 |
| 2024 | −$89.0m | — | −243.4% | −$1.65 |
| 2023 | −$104.7m | — | −1,192.5% | −$2.38 |
| 2022 | −$101.1m | — | −814.7% | −$2.60 |
| 2021 | −$85.8m | — | — | −$2.34 |
| 2020 | −$52.2m | — | — | — |
| 2019 | −$32.3m | — | — | — |
| 2018 | −$12.5m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Stoke Therapeutics net income compared with its sector
By net income for its latest fiscal year, Stoke Therapeutics ranks 186th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Stoke Therapeutics, −3.7%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 184th | Assembly Biosciences | −$6.1m | −8.5% |
| 185th | Protalix Biotherapeutics | −$6.6m | −12.5% |
| 186th | Stoke Therapeutics | −$6.9m | −3.7% |
| 187th | Neogen | −$7.9m | −0.9% |
| 188th | Bruker | −$8.6m | −0.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Stoke Therapeutics
- How much did Stoke Therapeutics earn in fiscal 2025?
- Stoke Therapeutics reported a net loss of $6.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $89.0m.
- What are the earnings per share of Stoke Therapeutics?
- They were −$0.12 in fiscal 2025, compared with −$1.65 in fiscal 2024.
- Where does Stoke Therapeutics rank in its sector by net income?
- It ranks 186th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Stoke Therapeutics come from?
- From the annual report (Form 10-K) that Stoke Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Stoke Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Stoke Therapeutics: the Stoke Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.